CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 5.91: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.98BCNY445.12M · vs all stocks (USD)
Trailing P/E
187.50xvs Biotechnology peers
Revenue (TTM)
361.40MCNY53.93M · vs all stocks (USD)
Profit Margin
4.75%vs Biotechnology peers
Beta
0.1850xvs all stocks
52-Week Change
-27.42%vs all stocks
Market Capitalization
2.98BCNY445.12M · vs all stocks (USD)
Enterprise Value
2.88BCNY430.44M · vs all stocks (USD)
Trailing P/E
187.50xvs Biotechnology peers
Forward P/E
36.29xvs Biotechnology peers
Price to Sales (TTM)
8.25xvs Biotechnology peers
Price to Book (MRQ)
5.32xvs Biotechnology peers
Enterprise to Revenue
7.98xvs Biotechnology peers
Enterprise to EBITDA
76.18xvs Biotechnology peers
Gross Margin
75.59%vs Biotechnology peers
Profit Margin
4.75%vs Biotechnology peers
Operating Margin
1.56%vs Biotechnology peers
Return on Assets (TTM)
1.41%vs Biotechnology peers
Return on Equity (TTM)
1.20%vs Biotechnology peers
Revenue (TTM)
361.40MCNY53.93M · vs all stocks (USD)
Revenue per Share (TTM)
1.31CNYUpdated Sep 20, 2026Quarterly Revenue Growth
-23.60%vs Biotechnology peers
Gross Profit (TTM)
274.37MCNY40.94M · vs all stocks (USD)
EBITDA (TTM)
60.16MCNY8.98M · vs all stocks (USD)
Net Income (TTM)
17.18MCNY2.56M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-44.40%vs Biotechnology peers
Operating Cash Flow (TTM)
25.42MCNY3.79M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-678.21KCNY-101.20K · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-82.25MCNYFY2025 · Dec 31, 2025Revenue
387.75MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
88.67MCNYFY2025 · Dec 31, 2025Gross Profit
299.08MCNYFY2025 · Dec 31, 2025Operating Income
35.13MCNY5.24M · vs all stocks (USD)
Pre-tax Income
27.28MCNYFY2025 · Dec 31, 2025Income Tax Expense
12.49MCNYFY2025 · Dec 31, 2025Net Income
14.79MCNYFY2025 · Dec 31, 2025EBIT
31.32MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
60.16MCNYFY2025 · Dec 31, 2025Research & Development
40.97MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
128.63MCNYFY2025 · Dec 31, 2025Other Operating Expenses
7.46MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
663.46KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
4.04MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0900CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0900CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
270.51MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
270.51MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
14.79MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
9.56MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
36.32MCNYFY2025 · Dec 31, 2025Free Cash Flow
-1.82MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
160.60MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
14.79MCNYFY2025 · Dec 31, 2025Other Non-cash Items
4.99MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
17.76MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.22MCNYFY2025 · Dec 31, 2025Capital Expenditures
-38.14MCNYFY2025 · Dec 31, 2025Net Acquisitions
-898.38KCNYFY2025 · Dec 31, 2025Purchase of Investments
-300.00KCNYFY2025 · Dec 31, 2025Sale of Investments
3.14MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-36.19MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
45.01MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-20.01MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-3.67MCNYFY2025 · Dec 31, 2025Other Financing Charges
-315.87KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
21.02MCNYFY2025 · Dec 31, 2025Shares Outstanding
265.16MSharesUpdated Sep 20, 2026Float Shares
199.76MSharesUpdated Sep 20, 2026% Held by Insiders
30.54%vs all stocks
% Held by Institutions
2.57%vs all stocks
Total Cash (MRQ)
145.76MCNY21.75M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5500CNYUpdated Sep 20, 2026Total Debt (MRQ)
135.19MCNY20.17M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2730xvs Biotechnology peers
Current Ratio (MRQ)
2.06xvs Biotechnology peers
Book Value per Share (MRQ)
2.12CNYUpdated Sep 20, 2026Total Assets
806.53MCNY120.35M · vs all stocks (USD)
Total Current Assets
325.61MCNYFY2025 · Dec 31, 2025Total Liabilities
318.72MCNYFY2025 · Dec 31, 2025Total Non-current Assets
480.92MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
130.17MCNYFY2025 · Dec 31, 2025Total Current Liabilities
188.54MCNYFY2025 · Dec 31, 2025Cash
160.60MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
160.60MCNYFY2025 · Dec 31, 2025Accounts Receivable
52.45MCNYFY2025 · Dec 31, 2025Inventory
77.71MCNYFY2025 · Dec 31, 2025Accounts Payable
20.13MCNYFY2025 · Dec 31, 2025Short-term Debt
21.18MCNYFY2025 · Dec 31, 2025Other Current Liabilities
22.26MCNYFY2025 · Dec 31, 2025Long-term Debt
105.75MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
800.00KCNYFY2025 · Dec 31, 2025Common Stock (Book)
265.16MCNYFY2025 · Dec 31, 2025Retained Earnings
-297.58MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
487.82MCNY72.79M · vs all stocks (USD)
52-Week Low
10.19CNYUpdated Sep 20, 202652-Week High
18.00CNYUpdated Sep 20, 202652-Week Change
-27.42%vs all stocks
Beta
0.1850xvs all stocks
50-Day MA
11.45CNYUpdated Sep 20, 2026200-Day MA
13.65CNYUpdated Sep 20, 2026Avg 10-Day Volume
3.07MSharesUpdated Sep 20, 2026Avg 30-Day Volume
5.57MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.0600CNYUpdated Sep 20, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.76Profit Margin: 0.05
Financial Health
Altman Z-Score 5.91: safe zoneNotable
Altman Z-Score: 5.91
High earnings qualityNotable
Earnings Quality Score: 1.21
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Anhui Sunhere Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Clover Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guizhou Yibai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ClearPoint Neuro Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Nanjing Medlander Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Baotou Dongbao Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jw Pharmaceutical Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hangzhou Tianmu-Shan Pharmaceutical Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Kehua Bio-Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Posiflex Technology Inc.
3 interpretationsClose Below 40W SMA With ProfitabilityIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Insulet Corporation
3 interpretationsClose Below 40W SMA With ProfitabilityIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Sylvamo Corporation
3 interpretationsClose Below 40W SMA With ProfitabilityIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated